Previous close | 0.5350 |
Open | 0.5350 |
Bid | 0.5100 x N/A |
Ask | 0.6000 x N/A |
Day's range | 0.5350 - 0.5350 |
52-week range | 0.4900 - 1.7700 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 28 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alphamab Oncology (stock code: 9966.HK) announced the data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, were presented as a poster at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024).
Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and highlighted recent progress and upcoming milestones.
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed in Australia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody, for the treatment of HER2-expressing, advanced or metastatic solid tumors.